<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112634">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01918566</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB 298/12</org_study_id>
    <nct_id>NCT01918566</nct_id>
  </id_info>
  <brief_title>The Role of Endogenous GLP-1 (Glycolipoprotein) in Regulating Glucose Stimulated Brain Activity</brief_title>
  <official_title>The Role of Endogenous GLP-1 in Regulating Glucose Stimulated Brain Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our objective is to investigate neuro-anatomical correlates of the regulation of energy
      intake by means of functional MRI. Administration of glucose with and without lactisole and
      exendin as well as fructose is followed by functional brain MRI, and findings are correlated
      with serum GLP-1 levels as an endogenous satiety signal in humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Functional magnetic resonance imaging (fMRI) in healthy volunteers while they performed a working memory task: changes in cerebral blood flow and blood hormones from baseline to treatment</measure>
    <time_frame>changes from baseline to one hour after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Whole brain analysis with a cluster-level threshold was followed by an a priori defined region of interest analysis of the dorsolateral prefrontal cortex including a cluster-level threshold and family-wise error adjustment for multiple comparisons.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Exploratory Behavior</condition>
  <arm_group>
    <arm_group_label>300ml tap water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intragastric instillation of 300ml tap water via nasogastric tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose plus Lactisole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fructose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose and Exendin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intragastric instillation of 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tap water, lactisole</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Single intragastric instillation of 300ml tap water with 450ppm lactisole</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>tap water</intervention_name>
    <arm_group_label>300ml tap water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube</intervention_name>
    <arm_group_label>Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole</intervention_name>
    <arm_group_label>Glucose plus Lactisole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>25g Fructose in 300ml tap water</intervention_name>
    <arm_group_label>Fructose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39</intervention_name>
    <arm_group_label>Glucose and Exendin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>300ml tap water with 450ppm lactisole</intervention_name>
    <arm_group_label>tap water, lactisole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  right-handed healthy males, no drugs, non-smoking

        Exclusion Criteria:

          -  drug abuse, smoker, left-handed, claustrophobia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Beglinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 5, 2013</lastchanged_date>
  <firstreceived_date>May 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
